Unifying JIAC Agent Development with AWE

2009 ◽  
pp. 220-225 ◽  
Author(s):  
Marco Lützenberger ◽  
Tobias Küster ◽  
Axel Heßler ◽  
Benjamin Hirsch
Keyword(s):  
Agent Development

Advanced Streaming Agent Development (Phase 2A): Medium-Scale Testing of Advanced Agent Compounds

1997 ◽  
Author(s):  
Joseph L. Lifke ◽  
Ted A. Moore ◽  
J. Douglas ◽  
Robert E. Tapscott
Keyword(s):  
Development Phase ◽  
Medium Scale ◽  
Agent Development

scholarly journals The Role of IGF/IGF-IR-Signaling and Extracellular Matrix Effectors in Bone Sarcoma Pathogenesis

Cancers ◽  
2021 ◽  
Vol 13 (10) ◽  
pp. 2478
Author(s):  
George N. Tzanakakis ◽  
Eirini-Maria Giatagana ◽  
Aikaterini Berdiaki ◽  
Ioanna Spyridaki ◽  
Kyoko Hida ◽  
...  
Keyword(s):  
Extracellular Matrix ◽  
Bone Sarcoma ◽  
Response To Therapy ◽  
Targeted Therapeutics ◽  
Attractive Therapeutic Target ◽  
Bone Sarcomas ◽  
Agent Development ◽  
Insulin Like Growth Factors ◽  
Igf Signaling

Bone sarcomas, mesenchymal origin tumors, represent a substantial group of varying neoplasms of a distinct entity. Bone sarcoma patients show a limited response or do not respond to chemotherapy. Notably, developing efficient chemotherapy approaches, dealing with chemoresistance, and preventing metastasis pose unmet challenges in sarcoma therapy. Insulin-like growth factors 1 and 2 (IGF-1 and -2) and their respective receptors are a multifactorial system that significantly contributes to bone sarcoma pathogenesis. Whereas failures have been registered in creating novel targeted therapeutics aiming at the IGF pathway, new agent development should continue, evaluating combinatorial strategies for enhancing antitumor responses and better classifying the patients that could best benefit from these therapies. A plausible approach for developing a combinatorial strategy is to focus on the tumor microenvironment (TME) and processes executed therein. Herewith, we will discuss how the interplay between IGF-signaling and the TME constituents affects sarcomas’ basal functions and their response to therapy. This review highlights key studies focusing on IGF signaling in bone sarcomas, specifically studies underscoring novel properties that make this system an attractive therapeutic target and identifies new relationships that may be exploited. Potential direct and adjunct therapeutical implications of the extracellular matrix (ECM) effectors will also be summarized.

Agent Development Environment for Multi-agent System Design and Integration

2010 ◽  
Vol 43 (4) ◽  
pp. 96-101
Author(s):  
Pavel Tichý ◽  
Petr Kadera ◽  
Raymond J. Staron ◽  
Pavel Vrba ◽  
Vladimír Mařík
Keyword(s):  
System Design ◽  
Multi Agent System ◽  
Agent System ◽  
Development Environment ◽  
Multi Agent ◽  
Agent Development

scholarly journals Comparative standard in institutional epistemology

2019 ◽  
Vol 30 (3) ◽  
pp. 418-430
Author(s):  
Marko-Luka Zubcic
Keyword(s):  
Institutional Arrangements ◽  
Moral Conflict ◽  
Epistemic Value ◽  
Epistemic State ◽  
Epistemic States ◽  
The Social ◽  
Democratic Authority ◽  
Philosophical Framework ◽  
Lock In ◽  
Agent Development

Which epistemic value is the standard according to which we ought to compare, assess and design institutional arrangements in terms of their epistemic properties? Two main options are agent development (in terms of individual epistemic virtues or capabilities) and attainment of truth. The options are presented through two authoritative contemporary accounts-agent development by Robert Talisse?s understanding in Democracy and Moral Conflict (2009) and attainment of truth by David Estlund?s treatment, most prominently in Democratic Authority: A Philosophical Framework (2008). Both options are shown to be unsatisfactory because they are subject to problematic risk of suboptimal epistemic state lock-in. The ability of the social epistemic system to revise suboptimal epistemic states is argued to be the best option for a comparative standard in institutional epistemology.

Hereditary cancer syndromes as model systems for chemopreventive agent development

2016 ◽  
Vol 43 (1) ◽  
pp. 134-145 ◽  
Author(s):  
Farzana L. Walcott ◽  
Jigar Patel ◽  
Ronald Lubet ◽  
Luz Rodriguez ◽  
Kathleen A. Calzone
Keyword(s):  
Hereditary Cancer ◽  
Model Systems ◽  
Hereditary Cancer Syndromes ◽  
Chemopreventive Agent ◽  
Cancer Syndromes ◽  
Agent Development
Sign in / Sign up

Export Citation Format

Share Document